{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65","upperLimit":"84","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Response assessed by the European Group for Blood and Marrow Transplant (EBMT) criteria, modified to include nCR and VGPR from the international uniform response criteria (IMWG).\n\nProgressive disease (PD) required one or more of the following:\n\n\\>25% increased in serum monoclonal paraprotein (must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation) \\>25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation) \\>25% increased in plasma cells in a bone marrow aspirate or on trephine biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.\n\nDevelopment of new bone lesions or soft tissue plasmacytomas (not including compression fracture).\n\nDevelopment of hypercalcemia (corrected serum calcium \\>11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients were treated for up to 8 21-day cycles with the combination of bortezomib 1.0 mg/m2 IV, days 1, 4, 8, and 11, and oral lenalidomide 15 mg/day, days 1 through 14, with oral dexamethasone 40 mg/day (cycles 1-4) and 20 mg/day (cycles 5-8) on the days of and days after bortezomib dosing (days 1, 2, 4, 5, 8, 9, 11, and 12).Following a protocol amendment , dexamethasone dosing was reduced to 20 mg/day in cycles 1 through 4 and 10 mg/day in cycles 5 through 8.\n\nBeyond cycle 8, responding patients and those with stable disease (SD) could receive maintenance therapy until disease progression or unacceptable toxicity. Maintenance therapy comprised bortezomib and lenalidomide at the doses tolerated on completion of cycle 8, with lenalidomide on days 1 through 14 and using an amended schedule of weekly bortezomib (days 1 and 8) and dexamethasone 10 mg on days 1, 2, 8, and 9.","id":"OG000","title":"Lenalidomide, Dexamethasone, Bortezomib Combination"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 months after therapy","title":"The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months","type":"PRIMARY","unitOfMeasure":"percentage of treated patients"}